Cyramza patent expiration?

When does the Cyramza (ramucirumab) patent expire?

Cyramza (ramucirumab) patent-expiration timing depends on which specific patent and jurisdiction you mean, because drug patents are granted per country and often have multiple layers (compound, formulation, use, and related regulatory-protection mechanisms). Without the exact patent numbers and geography, there is no single expiration date that applies everywhere.

Which patents control generic or biosimilar entry for Cyramza?

For biologics like ramucirumab, market entry is typically governed by a mix of:
- Individual patent families (with their own filing dates, grant dates, and term calculations)
- Country-specific extensions (where available)
- Regulatory exclusivities (which may differ from patent terms)
- Litigation outcomes that can delay entry even if a patent term is close to expiring

Those moving parts mean you generally need the specific patent list in the relevant country (and whether the question is about biosimilars vs. other product types).

What’s the difference between patent expiration and biosimilar approval timing?

Patent expiration answers when competitors may be free from patent barriers, but biosimilar launch timing can still be pushed by:
- Regulatory review timelines
- Patent litigation or settlements
- Remaining secondary patents that haven’t expired yet
- Country-specific exclusivity rules that provide additional protection beyond the first patent

So a “patent expiration” date does not always equal the first commercial day a biosimilar can launch.

Why Cyramza’s “expiration date” searches often return conflicting answers

Search results can disagree because they may refer to:
- Different patent types (primary compound vs. method-of-use patents)
- Different countries (US vs. EU vs. UK vs. Japan, etc.)
- Different calculation bases (filed vs. granted, extensions, adjustments)
- Expiration vs. “last day of exclusivity” style concepts

To pin down a true “expiration,” you need the jurisdiction and the patent identifier.

What I need to give you an exact expiration date

If you share any of the following, I can help narrow to the correct expiration window:
1) Country (e.g., US, EU, UK, Japan)
2) Patent number(s) or patent family name(s) you’re looking at
3) Whether you mean biosimilar exclusivity/patent barriers or a specific type of patent (compound vs. use)

If you want, I can also map the likely time window by country

Tell me the jurisdiction you care about (US or EU are the most common), and I’ll help you identify the relevant protection layers and how they typically translate into a practical “earliest possible entry” date.

Sources: None provided.